antibodi studi start june
takeaway post strong beat us eylea revenu despit
expect antibodi studi begin june result
possibl month afterward rais pt
eylea revenu beat weak april dupix also beat
us eylea revenu beat consensu slightli
estim despit encourag howev
impact overal demand especi diabet indic eylea mid-march
earli april though rebound seen recent week henc revenu
due new patient start could lower dupix us sale also strong
beat visibl alpha consensu like reflect abil patient dose
product home product favor safeti profil financi
result resili compani disclos expect peak impact
occur
antibodi cocktail enter clinic june may produc data within
continu optimist treatment develop program
particularli novel antibodi cocktail expect enter clinic next month
compani run trial prophylaxi pre-treat protect
non-hospit patient earlier diseas cours sever
hospit patient expect initi data could read fairli quickli
possibl eua approv though explicitli model program
model believ stock continu move reaction develop
increas price-to-earnings multipl increas pt
libtayo data impress lung cancer expect competit vs keytruda
encourag strong efficaci result libtayo phase non-smal
cell lung cancer nsclc studi recal studi end earli due
reduct risk death vs platinum doublet chemotherapi arm see note
although data similar keytruda note signific market opportun
first-lin nsclc billion vast major keytruda assum libtayo
captur market share keytruda would expect signific upsid current
maintain buy rais pt
maintain buy rate increas pt base
posit readout libtayo nsclc go forward continu expect strong
growth dupix libtayo eylea diabet indic also
encourag sanofi agreement restructur could give wholly-
own product increas oper margin see pipelin
potenti addit indications/opportun eylea market product
addit sourc valu stock
biotech
discov invent manufactur
commerci medicin treat seriou
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
buy unchang target price may
may dataphas data osteoarthr pain knee hipinterim phase datainterim analysi os nsclc monotherapyphas datapivot phase data patientsphas data r/r data potenti phase data potenti phase data r/r b-cell malignanciesfda decis sbla expand ad indic pediatr patient year phase dataphas studi asthma pediatr patient year old phase dataphas portion data eosinophil esophag patient figur cg vs consensu
buy unchang target price may
buy unchang target price may
buy unchang target price may
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u praluentu net product sale book praluentu ex-u ww zaltrapu ex-u ww kevzarau ex-u dupixentu ex-u regeneron pharmaceut
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may
obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price may
fy statementnet product sanofi collabor bayer healthcar collabor collabor total good option expensegross oper expensesresearch develop research develop sell gener administr sell gener administr collabor oper incom expens total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli share dilut share dilut share outstand regeneron pharmaceut
buy unchang target price may
fy pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer prepaid expens current asset total current asset market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens defer revenu sanofi current portion defer revenu current portion liabil total current liabil facil leas oblig defer revenu sanofi defer revenu liabil long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement
buy unchang target price may
fy statement flow net incom depreci non-cash compens non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market capit flow net proce issuanc common payment common stock tender employe tax repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
